Freenome reports higher precancer detection for updated CRC blood test
Freenome said on October 11 that an updated version of its SimpleScreen CRC blood test detected advanced precancerous lesions with 18.2% sensitivity, versus 13.7% in the earlier study. Sensitivity for lesions with high-grade dysplasia increased to 41.9% from 30.5%, while colorectal cancer sensitivity was 80.4% at 90% specificity. Freenome will present the detailed findings at the ACG 2026 Annual Meeting on October 14; Abbott Cancer Diagnostics launched the FDA-approved first-generation test in the United States in late September.
Why it matters
The updated test shows better detection of precancerous lesions but no reported improvement in colorectal cancer sensitivity, leaving investors to assess the commercial significance of the gain. Freenome shares fell 11% in the reaction reported by material 5, while a five-analyst consensus cited there projects revenue rising from $102 million in fiscal 2026 to $208 million in fiscal 2028.
Key facts
- 1The updated test detected advanced precancerous lesions with 18.2% sensitivity, compared with 13.7% in the original study. stocktitan.net
- 2Sensitivity for advanced precancerous lesions with high-grade dysplasia rose to 41.9% from 30.5%. rttnews.com
- 3The updated test recorded 80.4% sensitivity for colorectal cancer at 90% specificity. rttnews.com
- 4Freenome is scheduled to present the detailed results on October 14, 2026, at the ACG 2026 Annual Meeting. rttnews.com
- 5A consensus of five analysts cited on August 20 projected revenue of $102 million in fiscal 2026 and $208 million in fiscal 2028. finance.yahoo.com
Open questions
- The materials do not state whether the updated version has received FDA clearance or when it could be commercially launched.
- The revenue figures in material 5 are analyst consensus estimates rather than company guidance.
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.